UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED) June 1427, 2006

DURAVEST, INC

(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)

FLORIDA		0-27489		65-0924320
(STATE OR OTHER JURISDICTION OF INCORPORATION)		(COMMISSION FILE NUMBER)		(IRS EMPLOYER IDENTIFICATION NUMBER)

101 N. Wacker Drive, Suite 2006, Chicago, IL 60606

(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES, INCLUDING ZIP CODE)

REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE (312) 525-8160

____________________________________________

(FORMER NAME OR FORMER ADDRESS, IF CHANGED SINCE LAST REPORT)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

* ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

* ¨ Soliciting materials pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

* ¨ Pro-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

* ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Section 8. - ~~Matters~~Other ~~Related to Accountants and Financial Statements~~ Events

Item 48.01 ~~Changes~~Other ~~in Registrant’s Certifying Accountant~~Events

On June 14 27, 2006, we ~~engaged~~issued ~~Blackman~~a ~~Kallick~~press ~~Bartelstein,~~release ~~LLP~~announcing ~~("BK")~~the asappointment ~~our~~of ~~new independent~~RSM ~~auditing firm~~McGladrey, Inc., ~~Prior~~a tobusiness ~~the engagement of BK~~consulting, weaccounting ~~did~~and ~~not~~tax ~~consult with such~~ firm ~~regarding~~that ~~the~~focuses ~~application~~on ~~of accounting principles to a specific~~mid-sized ~~or contemplated transaction~~ companies, orto ~~any~~provide ~~matter~~value ~~that~~calculations ~~was~~for ~~either~~certain ~~the~~intangible ~~subject~~assets of a ~~disagreement~~ our Estracure orsubsidiary. aThese ~~reportable~~value ~~event.~~calculations Wewill ~~also~~assist ~~did~~management ~~not~~in complying ~~consult~~ with ~~BK regarding~~ the ~~type~~requirements of ~~audit~~SFAS ~~opinion~~141 ~~which~~in ~~might~~the bepreparation ~~rendered~~of on our financial ~~statements~~ ~~and~~ statements. noA ~~oral~~copy orof ~~written~~that ~~report~~press ~~was~~release ~~provided~~is bybeing BKfiled as an exhibit hereto.

On June 15 28, 2006, we issued a press release ~~relating~~reporting tosignificant ~~these~~progress ~~events~~by our Estracure subsidiary in moving towards a next-generation drug-eluting stent based on 17 beta estradiol. A copy of that press release is being filed as an exhibit hereto.

Section 9. - Financial Statements and Exhibits

Item 9.01

Financial Statements and Exhibits

(d)

Exhibits

Exhibit No. Description of Exhibits

Exhibit No.		Description of Exhibits

12(a)		Press Release dated June 27, 2006.

12(b)		Press Release dated June 28, 2006.

12(a) Press Release dated June 15, 2006.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	~~DURAVEST, INC.~~		DURAVEST, INC.
Dated: June 15, 2006	By:	/s/ Dr. Ogan Gurel
Dated: June 29, 2006		By:	/s/ Dr. Ogan Gurel
		~~Dr. Ogan Gurel, President and Chief~~	Dr. Ogan Gurel, President and Chief
		~~Executive, Officer and a Director~~	Executive, Officer and a Director

Filing Compare · DURAVEST INC